Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT])

American Journal of Cardiology

Volumn 92, Issue 4, 2003, Pages 400-405

  Felmeden, Dirk C ^a   Spencer, Charles G C ^a   Chung, Natali A Y ^a   Belgore, Funmi M ^a   Blann, Andrew D ^a   Beevers, D Gareth ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTILIPEMIC AGENT; ATENOLOL; ATORVASTATIN; BENDROFLUMETHIAZIDE; CHOLESTEROL; MARKER; PERINDOPRIL; THROMBOPLASTIN; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOTHELIUM INJURY; FEMALE; FUTUROLOGY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MEASUREMENT; PRIORITY JOURNAL; SCORING SYSTEM; STUDY; THROMBOGENESIS; VASODILATATION;

EID: 0043065525     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00657-X     Document Type: Article

References (30)

1. Kannel W.B., McGee D., Gordon T. A general cardiovascular risk profile; the Framingham Study. Am J Cardiol. 38:1976;46-51.
2. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S.E., McInnes G.T., Mehlsen J., et al. Anglo-Scandinavian Cardiac Outcomes Trial. A brief history, rationale and outline protocol. J Hum Hypertens. 15:(suppl 1):2001;S11-S12.
3. Leng G.C., Fowkes F.G. The Edinburgh Claudication Questionnaire an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys . J Clin Epidemiol. 45:1992;1101-1109.
4. D'Agostino R.B., Grundy S., Sullivan L.M., Wilson P. Validation of the Framingham coronary heart disease prediction scores. JAMA. 286:2001;180-187.
5. Belgore F.M., Blann A.D., Lip G.Y.H. Measurement of free and complexed soluble VEGF receptor Flt-1 (sFlt-1) in fluid samples. Clin Sci. 100:2001;567-575.
6. Clarkson P., Celermajer D.S., Powe A.J., Donald A.E., Henry R.M., Deanfield J.E. Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease. Circulation. 96:1997;3378-3383.
7. Anderson T.J., Uehata A., Gerhard M.D., Meredith I.T., Lieberman E.H., Knab S., Delagrange S., Leiberman E.H., Ganz P., Creager M., Yeung A.C., Selwyn A.P. Close relationship of endothelial dysfunction in human coronary and peripheral circulations. J Am Coll Cardiol. 26:1995;1235-1241.
8. Blann A.D., Waite M.A. von Willebrand factor and soluble E-selectin in hypertension influence of treatment and value in predicting the progression of atherosclerosis . Coronary Artery Dis. 7:1996;143-147.
9. Muiesan M.L., Salvetti M., Monteduro C., Rizzoni D., Zulli R., Corbellini C., Brun C., Agabiti-Rosei E. Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension. Hypertension. 33:1999;575-580.
10. Iiyama K., Nagano M., Yo Y., Nagano N., Kamide K., Higaki J., Mikami H., Ogihara T. Impaired endothelial function with essential hypertension assessed by ultrasonographgy. Am Heart J. 132:1996;779-782.
11. Belgore F., Blann A.D., Li-Saw-Hee F.L., Beevers D.G., Lip G.Y.H. Plasma levels of vascular endothelial growth factor and its soluble receptor (sFlt-1) in essential hypertension. Am J Cardiol. 87:2001;805-807.
12. Blann A.D., Lip G.Y.H. The endothelium in atherothrombotic disease assessment of function, mechanisms and clinical implications . Blood Coag Fibrinolys. 9:1998;297-306.
13. Blann A.D., Naqvi T., Waite M., McCollum C.N. von Willebrand factor and endothelial damage in essential hypertension. J Hum Hypertens. 7:1993;107-111.
14. Jansson J.-H., Nilsson T.K., Johnson O. von Willebrand factor in plasma a novel risk factor for recurrent myocardial infarction and death . Br Heart J. 66:1991;351-355.
15. Thompson G.S., Kienast J., Pyke S., Haverkate F., van de Loo J.C. Haemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 332:1995;635-641.
16. Jager A., van Hinsbergh V.W.M., Kostense P.J., Emeis J.J., Yudkin J.S., Nijpels G., et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects. Arterioscler Thromb Vasc Biol. 19:1999;3071-3078.
17. Blann A.D., Amiral J., McCollum C.N., Lip G.Y.H. Differences in free and total tissue factor pathway inhibitor, and tissue factor in peripheral artery disease compared to healthy controls. Atherosclerosis. 152:2000;29-34.
18. Soejima H., Ogawa H., Yasue H., Suefuji H., Kakita K., Tsuji I., Kumeda K., Aoyama K., Aoyama N. Effects of enalapril on tissue factor in patients with uncomplicated myocardial infarction. Am J Cardiol. 78:1996;336-340.
19. Toschi V., Gallo R., Lettino M., Fallon J.T., Gertz S.D., Fernandez-Ortiz A., Chesebro J.H., Badimon L., Nemerson Y., Fuster V., Badimon J.J. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation. 95:1997;594-599.
20. Taubman M.B., Fallon J.T., Schecter A.D., Giesen P., Mendlowitz M., Fyfe B.S., Marmur J.D., Nemerson Y. Tissue factor in the pathogenesis of atherosclerosis. Thromb Haemost. 78:1997;200-204.
21. Zumbach M., Hofmann M., Borcea V., Luther T., Kotzsch M., Muller M., Hergesell O., Andrassy K., Ritz E., Ziegler R., Wahl P., Nawroth P.P. Tissue factor antigen is elevated in patients with microvascular complications of diabetes mellitus. Exp Clin Endocrinol Diabetes. 105:1997;206-212.
22. Matetzky S., Tani S., Kangavari S., Dimayuga P., Yano J., Xu H., Chyu K.Y., Fishbein M.C., Shah P.K., Cercek B. Smoking increases tissue factor expression in atherosclerotic plaques implications for plaque thrombogenicity . Circulation. 102:2000;602-604.
23. Muller D.N., Mervaala E.M., Dechend R., Fiebeler A., Park J.K., Schmidt F., Theuer J., Breu V., Mackman N., Luther T., et al. Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy. Am J Pathol. 157:2000;111-122.
24. Blann A.D., Belgore F.M., Constans J., Conri C., Lip G.Y.H. Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with hyperlipidemia and atherosclerosis and the effect of lipid-lowering therapy. Am J Cardiol. 87:2001;1160-1163.
25. Blann A.D., Belgore F.M., McCollum C.N., Silverman S., Lip P.L., Lip G.Y.H. Vascular endothelial growth factor and its receptor Flt-1 in the plasma of patients with coronary and peripheral atherosclerosis and type II diabetes. Clin Sci. 102:2002;187-194.
26. Felmeden D.C., Blann A.D., Lip G.Y.H. Angiogenesis basic pathophysiology and implications for disease . Eur Heart J. 24:2003;586-603.
27. Le Noble F.A.C., Stassen F.R.M., Hacking W.J.G., Struijker Boudier H.A.J. Angiogenesis and hypertension. J Hypertens. 16:1998;1563-1572.
28. Paniagua O.A., Bryant M.B., Panza J.A. Role of endothelial nitric oxide in shear stress-induced vasodilation of human microvasculature. Circulation. 103:2001;1752-1758.
29. McAllister A.C. Basal nitric oxide production is impaired in offspring of patients with essential hypertension. Clin Sci. 97:1999;141-147.
30. John S., Schmieder R.E. Impaired endothelial function in arterial hypertension and hypercholesterolemia potential mechanisms and differences . J Hypertens. 18:2000;363-374.